Allogeneic Hematopoietic Stem Cell Transplantation Against Recurrent Rhabdomyosarcoma

Ohta, Hiroyuki; Hashii, Yoshiko; Yoshida, Hisao; Kusuki, Shigenori; Tokimasa, Sadao; Yoneda, Akihiro; Fukuzawa, Masahiro; Inoue, Nami; Hara, Junichi; Kusafuka, Takeshi; Ozono, Keiichi

doi:10.1097/mph.0b013e3181e7ddc5

Cited by 10 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one report of a high-risk case, a long-term disease-free survival was achieved with allogeneic hematopoietic stem cell transplantation in order to induce a graft-versus-tumor effect (52). In our high-risk patient, the use of modified alternative VDC and EI therapy followed by radiation for the primary lesion successfully induced and maintained complete remission for 15 months.…”

Section: Discussionmentioning

confidence: 98%

Bone Marrow Metastasis of Rhabdomyosarcoma Mimicking Acute Leukemia: A Case Report and Review of the Literature

et al. 2015

View full text Add to dashboard Cite

Bone marrow metastasis of rhabdomyosarcoma has been reported to be difficult to distinguish from acute leukemia. We herein describe a case of rhabdomyosarcoma with bone marrow metastasis mimicking acute lymphoblastic leukemia. A 29-year-old woman was admitted with thrombocytopenia, blast-like cells in the peripheral blood and a coagulation disorder. Bone marrow aspirates showed 94.8% blast-like cell infiltration (CD45 -, myeloperoxidase -, and CD56 + ), and CT scan revealed the presence of an infiltrating mass in the nasal cavity. Based on a biopsy of the nasal cavity, the patient was diagnosed with rhabdomyosarcoma exhibiting bone marrow metastasis. She received chemotherapy, followed by radiation therapy, and has since remained alive for 26 months, as of the last follow-up.

show abstract

Section: Discussionmentioning

confidence: 98%

Bone Marrow Metastasis of Rhabdomyosarcoma Mimicking Acute Leukemia: A Case Report and Review of the Literature

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The rationale for treating cancer patients with allogeneic grafts is a hypothesised graft- vs -tumour effect of donor-derived cytotoxic T cells and/or natural killer cells that may unavoidably be given during infusion of haematopoietic stem cells for immune reconstitution or intentionally thereafter as DLI ( Childs et al , 2000 ; Ueno et al , 2003 ; Bishop et al , 2004 ; Bregni et al , 2004 ; Kolb et al , 2004 ; Lundqvist and Childs, 2005 ; Mackensen et al , 2006 ; Rizzo et al , 2009 ; Reisner et al , 2011 ). Little is known about graft- vs -RMS effects in patients treated with allo-SCT and only few single-centre case experiences have been reported ( Misawa et al , 2003 ; Donker et al , 2009 ; Ohta et al , 2011 ). In this study, we evaluated individual therapy outcomes of 30 patients with advanced RMS of all subtypes who became eligible for experimental allo-SCT.…”

Section: Discussionmentioning

confidence: 99%

“…These observations suggest that allo-SCT and cellular immunotherapy may also improve outcome for RMS patients. However, little is known about graft- vs -RMS effects in patients treated with allo-SCT and only few single-centre case experiences have been reported ( Misawa et al , 2003 ; Donker et al , 2009 ; Ohta et al , 2011 ).…”

mentioning

confidence: 99%

Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment

et al. 2013

View full text Add to dashboard Cite

Background:Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported.Methods:We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor lymphocyte infusions (DLIs). Median follow-up was 9 months.Results:Three-year OS was 20% (s.e.±8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s.e.±10%) and 11% (s.e.±6%) for death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR.Conclusion:The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for consolidating CR, but this needs to be validated in prospective trials.

show abstract

“…However, ~15% of patients with RMS have high-risk stage IV diseases with bone marrow (BM) involvement and a poor clinical outcome, with a three-year survival rate of ~15% (1,2). The use of myeloablative chemotherapy in combination with autologous BM or peripheral blood stem cell transplantation rescue may be required to treat children with stage IV disease (3,4). Thus, the detection of BM involvement at diagnosis is critical for accurate staging and risk assessment.…”

Section: Introductionmentioning

confidence: 99%

Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry

et al. 2014

View full text Add to dashboard Cite

Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The detection of contaminating RMS cells in the bone marrow (BM) is important in clinical staging and risk assessment. The cytological examination of the BM remains the gold standard for the diagnosis of RMS, but has a limited sensitivity. In the present study, 32 BM and two cerebrospinal fluid (CSF) samples from 11 patients with suspected metastasis were analyzed by flow cytometry (FCM) with ganglioside D2 (GD2) conjugated with fluorescein isothiocyanate, cluster of differentiation (CD)90-phycoerythrin, CD45-peridinin chlorophyll protein and CD56-allophycocyanin monoclonal antibody cocktail in parallel to morphological examination at diagnosis or during treatment. Five samples (14.7%) were positive for RMS onup morphological examination. By FCM, 16 samples (47.1%) were positive for RMS. A significant difference was identified between the two methods. The four-color FCM assay successfully detected RMS cells in BM samples to a level of 0.01% (1 per 104 cells). RMS cells demonstrated a phenotype with CD56+/CD90+/CD45−/GD2− expression, which is different from the CD56+/CD90+/CD45−/GD2+ expression phenotype in neuroblastoma cells. The follow-up of four patients by FCM demonstrated that two patients became minimal residual disease-negative following two and four cycles of chemotherapy, respectively, and survived. The other two cases remained FCM-positive despite receiving four courses of chemotherapy and consequently succumbed to progressive disease. In addition, FCM analysis of the CSF samples from one patient confirmed a diagnosis of CSF metastasis with RMS. In conclusion, FCM may have a role not only in staging and monitoring the effects of therapy, but also in providing diagnostic confirmation of CSF metastasis with RMS.

show abstract

Allogeneic Hematopoietic Stem Cell Transplantation Against Recurrent Rhabdomyosarcoma

Cited by 10 publications

References 0 publications

Bone Marrow Metastasis of Rhabdomyosarcoma Mimicking Acute Leukemia: A Case Report and Review of the Literature

Bone Marrow Metastasis of Rhabdomyosarcoma Mimicking Acute Leukemia: A Case Report and Review of the Literature

Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment

Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry

Contact Info

Product

Resources

About